Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Guidelines for safer handling of cytotoxics

ECCO 15 - ESMO 34

20 - 24 Sep 2009

Published: 3 Nov 2009

Views: 12210

Rating:

Save

Dr Klaus Meier - President of the European Society of Oncology Pharmacy

Dr Klaus Meier, President of the European Society of Oncology Pharmacy, discusses the society's latest work of preparing centralised guidelines for the preperation of cytotoxic treatments with managing editor Professor Gordon McVie, at ECCO 15 - ESMO 34, Berlin, 2009.

Related Videos

Blood test may identify patients with non-small cell lung cancer subtype who...

Dr Pasi A. Jänne - Dana-Farber Cancer Institute, Boston, USA

Blood test may identify patients with non-small cell lung cancer subtype who can benefit from combination therapy ( Dr Pasi A. Jänne - Dana-Farber Cancer Institute, Boston, USA )

Chemo-immunotherapy combo nivolumab and nab-paclitaxel could be effective...

Dr Chiara Mercinelli - San Raffaele Scientific Institute, Milan, Italy

Chemo-immunotherapy combo nivolumab and nab-paclitaxel could be effective perioperative strategy for MIBC ( Dr Chiara Mercinelli - San Raffaele Scientific Institute, Milan, Italy )

EAU 2024: Bladder cancer latest

Dr Bernadett Szabados, Dr Félix Guerrero-Ramos, Dr Yohann Loriot, Prof Andrea...

EAU 2024: Bladder cancer latest ( Dr Bernadett Szabados, Dr Félix Guerrero-Ramos, Dr Yohann Loriot, Prof Andrea Necchi and Dr Cosimo De Nunzio )

ELCC 2024: Latest in EGFR mutant lung cancer; exon 20 mutation focus

Dr Anna Minchom, Prof Enriqueta Felip, Prof Nicolas Girard and Prof Pascale...

ELCC 2024: Latest in EGFR mutant lung cancer; exon 20 mutation focus ( Dr Anna Minchom, Prof Enriqueta Felip, Prof Nicolas Girard and Prof Pascale Tomasini )

Nab-paclitaxel as first line treatment of gastrointestinal neuroendocrine...

Dr Lorraine Chantrill - University of Sydney, Sydney, Australia

Nab-paclitaxel as first line treatment of gastrointestinal neuroendocrine carcinomas shows efficacious results ( Dr Lorraine Chantrill - University of Sydney, Sydney, Australia )

Trifluridine/tipiracil and bevacizumab combination gives a prolonged PFS...

Prof Hironaga Satake - Kochi Medical School, Kochi, Japan

Trifluridine/tipiracil and bevacizumab combination gives a prolonged PFS compared to trifluridine/tipiracil monotherapy in mCRC ( Prof Hironaga Satake - Kochi Medical School, Kochi, Japan )

Enfortumab vedotin in combination with pembrolizumab is a potential new...

Dr Michiel Simon Van Der Heijden - Netherlands Cancer Institute, Amsterdam...

Enfortumab vedotin in combination with pembrolizumab is a potential new standard of care for 1L la/mUC ( Dr Michiel Simon Van Der Heijden - Netherlands Cancer Institute, Amsterdam, Netherlands )

What's new on ADCs in management of advanced NSCLC

Dr David Planchard - Institute Gustave Roussy, Villejuif, France

What's new on ADCs in management of advanced NSCLC ( Dr David Planchard - Institute Gustave Roussy, Villejuif, France )

Nivolumab plus ipilimumab improves on chemo in previously untreated MSI-H/dMMR...

Dr Thierry André - Sorbonne Université, Paris, France

Nivolumab plus ipilimumab improves on chemo in previously untreated MSI-H/dMMR mCRC ( Dr Thierry André - Sorbonne Université, Paris, France )

More from ecancer